Revealing the structural basis of action of hERG potassium channel activators and blockers.

The Journal of Physiology
Matthew PerryJohn S Mitcheson

Abstract

Human ether-á-go-go related gene (hERG) potassium (K(+)) channels play a critical role in cardiac action potential repolarization. This is due, in large part, to the unique gating properties of these channels, which are characterized by relatively slow activation and an unusually fast and voltage-dependent inactivation. A large number of structurally diverse compounds bind to hERG and carry an unacceptably high risk of causing arrhythmias. On the other hand, drugs that increase hERG current may, at least in principle, prove useful for treatment of long QT syndrome. A few blockers have been shown to increase hERG current at potentials close to the threshold for channel activation--a process referred to as facilitation. More recently, a novel group of hERG channel activators have been identified that slow deactivation and/or attenuate inactivation. Structural determinants for the action of two different types of activators have been identified. These compounds bind at sites that are distinct from each other and also separate from the binding site of high affinity blockers. They reveal not only novel ways of chemically manipulating hERG channel function, but also interactions between structural domains that are critical to normal ...Continue Reading

References

May 1, 1996·The Journal of General Physiology·P S SpectorM C Sanguinetti
Mar 5, 1998·Circulation Research·E FickerA M Brown
Sep 16, 1998·The American Journal of Cardiology·D M Roden
Feb 29, 2000·The Journal of General Physiology·J S MitchesonM C Sanguinetti
Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·J S MitchesonM C Sanguinetti
Jul 17, 2001·Molecular Pharmacology·K KamiyaM C Sanguinetti
Feb 28, 2002·The Journal of General Physiology·Paula L Smith, Gary Yellen
Apr 19, 2002·The Journal of Biological Chemistry·Jose A Sánchez-ChapulaMichael C Sanguinetti
May 31, 2002·Nature·Youxing JiangRoderick MacKinnon
Sep 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jun ChenMichael C Sanguinetti
Oct 31, 2002·The Journal of General Physiology·Jie LiuGea-Ny Tseng
Jul 4, 2003·British Journal of Pharmacology·James T MilnesHarry J Witchel
Aug 21, 2003·Proceedings of the National Academy of Sciences of the United States of America·David R PiperMartin Tristani-Firouzi
Sep 19, 2003·The Journal of Biological Chemistry·Alain J LabroDirk J Snyders
Dec 31, 2003·The Journal of Biological Chemistry·David FernandezMichael C Sanguinetti
May 12, 2004·Journal of Molecular and Cellular Cardiology·John M RidleyJules C Hancox
Jun 8, 2004·The Journal of Physiology·Rajesh N SubbiahJamie I Vandenberg
Jul 22, 2004·Molecular Pharmacology·Matthew PerryJohn Mitcheson
Nov 6, 2004·The Journal of Biological Chemistry·David R PiperMartin Tristani-Firouzi
Nov 17, 2004·The Journal of General Physiology·Mei ZhangGea-Ny Tseng
Nov 20, 2004·Nature Reviews. Neuroscience·Kenton J Swartz
Jul 9, 2005·Science·Stephen B LongRoderick Mackinnon
Sep 10, 2005·The Journal of Physiology·Min JiangGea-Ny Tseng
Nov 15, 2005·Molecular Pharmacology·Oscar CasisMichael C Sanguinetti
Feb 14, 2006·Molecular Pharmacology·Kaichiro KamiyaMichael C Sanguinetti
Aug 25, 2006·The Journal of Pharmacology and Experimental Therapeutics·Haoyu ZengXiaoping Xu
Oct 24, 2006·Biochemical and Biophysical Research Communications·James T MilnesJules C Hancox
Jun 27, 2007·British Journal of Pharmacology·D StorkS Hering
Aug 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Matthew PerryMichael C Sanguinetti

❮ Previous
Next ❯

Citations

Jun 24, 2011·Pflügers Archiv : European journal of physiology·Iván A Aréchiga-FigueroaJosé A Sánchez-Chapula
May 31, 2011·Acta Pharmacologica Sinica·Ping-zheng ZhouZhao-bing Gao
Aug 13, 2013·Archives of Toxicology·Sara F FerreiroLuis M Botana
Dec 24, 2013·Journal of Pharmacological and Toxicological Methods·Sean Ekins
Jun 20, 2014·Nucleic Acid Therapeutics·Cindy L BermanHusam S Younis
Apr 16, 2014·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Abeer Abu-ZeitoneArthur J Moss
Mar 17, 2015·Advanced Drug Delivery Reviews·Bruno O Villoutreix, Olivier Taboureau
Apr 14, 2016·Toxicology Letters·Marco GobbiMario Salmona
Jul 23, 2011·Biochimica Et Biophysica Acta·Yi H ZhangJules C Hancox
Aug 16, 2016·Proceedings of the National Academy of Sciences of the United States of America·Carol A HarleyJoão H Morais-Cabral
Nov 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·José Rivera-TorresVicente Andrés
Dec 15, 2012·Journal of Pharmacological Sciences·Mahoko AsayamaTetsushi Furukawa
Oct 13, 2016·Scientific Reports·Yibo WangSergei Yu Noskov
Feb 27, 2014·Scientific Reports·Mandeep S DhillonAsipu Sivaprasadarao
May 4, 2017·Medicinal Research Reviews·Subha Kalyaanamoorthy, Khaled H Barakat
May 13, 2017·Natural Product Reports·Jadel M KratzJudith M Rollinger
Mar 17, 2018·The Journal of Biological Chemistry·Matthew V HelliwellChristopher E Dempsey
Oct 1, 2012·Therapeutic Advances in Drug Safety·Senthil NachimuthuJeffrey M Schussler
Feb 22, 2018·Molecular Informatics·Daniel Șterbuleac, Călin Lucian Maniu
Dec 7, 2013·The Journal of Pharmacology and Experimental Therapeutics·Patrick ThurnerXaver Koenig
Jul 26, 2017·Clinical and Experimental Pharmacology & Physiology·JianHua HuoAiqun Ma
Sep 19, 2014·The Journal of Pharmacology and Experimental Therapeutics·Ping LiZhaobing Gao
Sep 10, 2017·British Journal of Pharmacology·John S Mitcheson, Jules C Hancox
Apr 4, 2020·Molecular Pharmacology·Muge QileMarcel A G van der Heyden
Sep 20, 2012·Physiological Reviews·Jamie I VandenbergAdam P Hill
Sep 3, 2010·The Journal of Physiology·Ian D ForsytheNicholas Dale
Aug 17, 2020·International Journal of Molecular Sciences·Laura van der SchoorMarcel A G van der Heyden
Jun 2, 2021·Journal of Molecular and Cellular Cardiology·Kevin R DeMarcoIgor Vorobyov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.